Business
The US-based, independently operated Institute for Clinical and Economic Review (ICER) has established a partnership with the UK’s National Institute for Health Care and Excellence (NICE) and the Canadian Agency for Drugs and Technologies in Health (CADTH), on how to measure value for high-cost gene therapies. What does this mean for the industry?